Proton magnetic resonance spectroscopy to study the metabolic changes in the brain of a patient with Leigh syndrome.
Localized proton magnetic resonance spectroscopy (MRS) was performed to study the metabolic changes in the brain of a patient with Leigh syndrome, who had a T-->G point mutation at nt 8993 of mitochondrial DNA. In this patient, sodium dichloroacetate therapy normalized the lactate and pyruvate levels in both blood and cerebrospinal fluid (CSF). However, his psychomotor retardation did not improve and magnetic resonance imaging showed progressive cerebral atrophy. In the patient's spectra, elevation of brain lactate was observed throughout the brain with regional variations, predominantly in the basal ganglia and brainstem with an abnormal MRI appearance. Although the lactate/creatine ratio observed on proton-MRS was related to the CSF lactate level, the ratio did not completely parallel the CSF lactate level, i.e. brain lactate was detected even when the CSF lactate level had become normalized. Furthermore, proton-MRS revealed a decrease in the N-acetylaspartate/creatine ratio and an increase in the choline/creatine ratio, representing neuronal loss and breakdown of membrane phospholipids. The clinical and MRI findings were well related to the changes in spectroscopically determined brain metabolites. These results indicate that the brain metabolites observed on proton-MRS are useful indicators of a response to therapy and prognosis in Leigh syndrome.
Takahashi
S
S
Department of Pediatrics, Asahikawa Medical College, Japan. staka@ncnaxp.ncnp.go.jp
Oki
J
J
Miyamoto
A
A
Okuno
A
A
D001921:Brain / Q000378:metabolism* / Q000473:pathology; D004272:DNA, Mitochondrial / Q000235:genetics*; D003999:Dichloroacetic Acid / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007773:Lactates / Q000097:blood / Q000134:cerebrospinal fluid; D007888:Leigh Disease / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D017354:Point Mutation; D011597:Psychomotor Performance; D011773:Pyruvates / Q000097:blood / Q000134:cerebrospinal fluid; D013831:Thiamine / Q000627:therapeutic use
D004272:DNA, Mitochondrial; D007773:Lactates; D011773:Pyruvates; D003999:Dichloroacetic Acid; D013831:Thiamine